Health Economics›Urothelial carcinoma›Locally advanced or metastatic disease refractory/intolerant to platinum chemotherapy and/or immune checkpoint inhibitor

Locally advanced or metastatic disease refractory/intolerant to platinum chemotherapy and/or immune checkpoint inhibitor

Urothelial carcinoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Sacituzumab govitecan monotherapy Variant #01 Partial	—	—	21d	—	10.3 mo	—	—	1
Enfortumab vedotin monotherapy Variant #01 Partial	—	—	28d	—	12.9 mo	—	—	1

2 of 2 regimens shown